AI Article Synopsis
- Immunotherapy has revolutionized treatment for malignant tumors, but pancreatic ductal adenocarcinoma (PDAC) shows a poor response due to its non-immunogenic nature.
- The tumor microenvironment (TME) and dense stroma of PDAC create barriers that impede drug delivery and immune cell infiltration, complicating immunotherapy effectiveness.
- Recent research on nanoparticle-based therapies indicates potential in improving drug delivery and modifying the immunosuppressive TME, thereby enhancing the effectiveness of immunotherapy for PDAC patients.
Article Abstract
Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment (TME) and its dense stroma, which acts as a barrier for drug delivery and immune cell infiltration. Recent studies have shown that nanoparticle-based therapeutic strategies have more promising applications in improving drug delivery and reversing the immunosuppressive TME for PDAC. Therefore, nanomaterial-based therapeutic approaches are expected to enhance the effectiveness of immunotherapy and improve prognosis of patients with PDAC. Here, we outline the status and dilemma of PDAC immunotherapy, and summarize the latest advances in nanoparticle-based treatment strategies to enhance the efficacy of PDAC immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607590 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics14102033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!